As healthcare shifts towards remote monitoring, connected devices and decentralized care, sensor technologies are becoming increasingly foundational to how medical devices collect, validate and transmit critical information. From remote patient monitoring and at-home care to connected medical devices and robotic-assisted surgery, sensing technologies can help enable earlier detection, more reliable clinical data and better-informed decision making.
Marks the first FDA-approved use of personalized molecular residual disease (MRD) testing to guide treatment decisions and solidifies Natera’s Treatment on MRD (TOMR) approach for MIBC care.
The next phase of digital mental health adoption depends less on innovation and more on how the industry uses real-world evidence, builds reimbursement frameworks, and applies regulatory precedent to accelerate scale.
Increasing patient demand, barriers to access, and elevated costs are pushing healthcare providers to reconsider traditional clinical and operational workflows to meet growing challenges and improve patient outcomes. Artificial intelligence (AI), robotics, and digital therapeutic solutions are streamlining processes and expanding the possibilities for reimagining care delivery. As these technologies converge, the shift from complex high-cost interventions toward lighter more adaptive care models creates opportunity to better meet the needs of diverse patient populations.
Holmes appears to be headed for prison after an appeals court rejected her bid to remain free while she tries to overturn her conviction in a blood-testing hoax that brought her fleeting fame and fortune.
Advancements in cardiac care and novel therapies are transforming cardiac medical devices, providing new solutions for millions affected by heart disease globally.
AI and real-time data enhance care efficiency and access. And with healthcare workers in short supply, the rapid advancements in AI, IoMT, and related innovation offer patient access freedom, enhanced care delivery, and better outcomes.
AI has the ability to revolutionize the medical landscape, but to enable this, Quality Engineering is critically important.
While pharmacogenomics has traditionally been the domain of academic research, policymakers are now showing a burgeoning interest in its potential to enhance patient outcomes and mounting evidence from the pharmaceutical industry is fueling interest in this field.
The Digital Medicine Society (DiMe) is partnering with PHTI, ZS, and other leading organizations to develop and launch core components of integrated evidence plans for digital health products to support faster regulatory approval and commercialization.
